AllStripes

AllStripes (formerly RDMD) was a San Francisco, California-based healthcare technology company founded in 2017 that focused on generating evidence for rare disease research and drug development. It operated a technology platform that collected, de-identified and structured patient medical records into research-ready (described in sources as regulatory-ready, FDA/EMA-oriented) real-world evidence datasets for biopharmaceutical companies and academic researchers, paired with a patient-facing application that let patients and families participate in treatment research online and access their own medical data [1][2][3].

The patient product was described as free to users, with patients retaining ownership of their data and the ability to withdraw at any time; users did not have to upload records themselves, as AllStripes handled retrieval [4]. One source describes the company as a public benefit corporation [3]. Research programs spanned rare conditions including Lesch-Nyhan disease, Crigler-Najjar syndrome type 1, methylmalonic acidemia and propionic acidemia (via the JUMP study with HemoShear Therapeutics), and long-chain fatty acid oxidation disorders [2][3].

In October 2023 AllStripes was acquired by PicnicHealth, a patient-centered healthcare evidence generation company, in a transaction whose financial terms were not disclosed. PicnicHealth stated the deal would incorporate AllStripes' patient experience into its own platform and expand its reach across patient communities. The allstripes.com domain now presents PicnicHealth's consumer product, which aggregates a user's medical records into a single view, offers a health assistant application and a clinical team that reviews records and builds a care plan, and invites patients to opt into research studies with pharmaceutical and academic partners [0][1][5][6].

Founding story

Nancy Yu, who had worked with biopharma companies and later at 23andMe on drug discovery, met rare disease patient advocate and technology developer Onno Faber in 2016. Faber had been diagnosed with neurofibromatosis (described as type 2 in [3] and [4]; source [2] states type 1) and was frustrated by a drug development process that excluded patients. The two co-founded the company in 2017 to make patients active participants in rare disease research and to unlock more treatment options for people with rare diseases [2][3][4].

Business model

AllStripes offered its platform free to rare disease patients and families, who contributed medical records and consented to research participation, and monetized through research collaborations and evidence-generation programs with biopharmaceutical companies, academic centers and patient advocacy organizations [2][3][4]. After the acquisition, the allstripes.com property markets a PicnicHealth consumer offering that references an active subscription, with lifetime digital access to records retained if a subscription ends [0].

Sources indicate revenue came from life sciences customers sponsoring real-world evidence studies and research programs rather than from patients, who used the platform free of charge [2][4].

Traction

As of the August 2021 Series B, AllStripes reported partnerships with more than 30 patient advocacy organizations across 40 conditions and support for more than 3,000 users; a December 2021 interview cited about 50 rare disease programs listed on the platform, with plans to add programs monthly [2][4]. One aggregator states the company scaled to over 100 employees prior to acquisition [3].

Latest developments

PicnicHealth announced the acquisition of AllStripes on 23 October 2023, stating it would fold AllStripes' patient experience into the PicnicHealth platform and continue both companies' work on patient-centered evidence generation; terms were undisclosed. AllStripes CEO Nancy Yu commented on the deal. The allstripes.com domain now hosts PicnicHealth's patient-facing product [0][1][5][6].